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Amiodarone​ ​is​ ​an​ ​extremely​ ​effective​ ​antiarrhythmic​ ​drug​ ​that​ ​is​ ​known​ ​to​ ​cause​ ​many 
adverse​ ​effects​ ​such​ ​as​ ​pulmonary,​ ​thyroid,​ ​and​ ​liver​ ​toxicities.​ ​Of​ ​these,​ ​pulmonary 
toxicity​ ​is​ ​most​ ​serious.​ ​Pulmonary​ ​toxicity​ ​can​ ​present​ ​as​ ​interstitial​ ​pneumonitis, 
organizing​ ​pneumonia,​ ​pulmonary​ ​nodules​ ​and​ ​masses,​ ​and​ ​very​ ​rarely​ ​pleural 
effusions.​ ​We​ ​present​ ​a​ ​case​ ​of​ ​a​ ​73-year-old​ ​male​ ​who​ ​presented​ ​with​ ​progressive 
exertional​ ​dyspnea,​ ​nonproductive​ ​cough,​ ​generalized​ ​fatigue,​ ​and​ ​weakness.​ ​He​ ​was 
found​ ​to​ ​have​ ​multiorgan​ ​toxicity​ ​secondary​ ​to​ ​long-term​ ​treatment​ ​with​ ​high​ ​doses​ ​of 
amiodarone.​ ​This​ ​case​ ​illustrates​ ​that​ ​amiodarone​ ​may​ ​cause​ ​toxicity​ ​involving​ ​multiple 
organs​ ​simultaneously​ ​in​ ​patients​ ​receiving​ ​long-term​ ​therapy​ ​and​ ​represents​ ​the​ ​first 





Amiodarone​ ​is​ ​a​ ​widely​ ​used​ ​Class​ ​III​ ​antiarrhythmic​ ​drug​ ​that​ ​can​ ​be​ ​utilized​ ​for​ ​the 
management,​ ​treatment,​ ​and​ ​prevention​ ​of​ ​ventricular​ ​and​ ​atrial​ ​arrhythmias.​ ​However, 
long-term​ ​use​ ​of​ ​amiodarone​ ​is​ ​limited​ ​secondary​ ​to​ ​its​ ​adverse​ ​effects.​ ​Pulmonary 
toxicity​ ​is​ ​the​ ​most​ ​adverse​ ​side​ ​effect,​ ​with​ ​an​ ​incidence​ ​that​ ​ranges​ ​from​ ​1%​ ​to​ ​10%, 




A​ ​73-year-old​ ​male​ ​presented​ ​to​ ​our​ ​service​ ​with​ ​complaints​ ​of​ ​worsening​ ​exertional 
dyspnea​ ​for​ ​1​ ​month​ ​duration.​ ​He​ ​had​ ​a​ ​medical​ ​history​ ​of​ ​coronary​ ​artery​ ​disease,​ ​with 
a​ ​previous​ ​coronary​ ​artery​ ​bypass​ ​grafting,​ ​hypertension,​ ​refractory​ ​ventricular 
tachycardia​ ​(VT)​ ​with​ ​a​ ​prior​ ​cardiac​ ​arrest,​ ​catheter​ ​ablation​ ​of​ ​VT,​ ​and​ ​an​ ​automated 
implantable​ ​cardioverter-defibrillator​ ​(AICD)​ ​insertion.​ ​He​ ​also​ ​reported​ ​chronic 
nonproductive​ ​cough,​ ​generalized​ ​weakness,​ ​fatigue,​ ​anorexia,​ ​malaise,​ ​and 
unintentional​ ​eight​ ​pounds​ ​weight​ ​loss​ ​over​ ​the​ ​last​ ​3​ ​months.​ ​He​ ​was​ ​maintained​ ​on 
amiodarone​ ​400​ ​mg/daily​ ​for​ ​the​ ​past​ ​3​ ​years​ ​due​ ​to​ ​recurrent​ ​episodes​ ​of​ ​VT​ ​and 
frequent​ ​AICD​ ​shocks.​ ​His​ ​vital​ ​signs​ ​were​ ​significant​ ​for​ ​a​ ​blood​ ​pressure​ ​110/70 
mmHg,​ ​heart​ ​rate​ ​76​ ​beats/min,​ ​respiratory​ ​rate​ ​23​ ​breaths/min,​ ​and​ ​oxygen​ ​saturation 
95%​ ​on​ ​room​ ​air.​ ​Physical​ ​examination​ ​was​ ​significant​ ​for​ ​decreased​ ​air​ ​entry​ ​over​ ​the 
left​ ​lung​ ​base.​ ​Laboratory​ ​workup​ ​showed​ ​white​ ​blood​ ​cell​ ​(WBC)​ ​count​ ​of​ ​7500/uL, 
hemoglobin​ ​level​ ​14.4​ ​g/dL,​ ​thyroid​ ​stimulating​ ​hormone​ ​<0.01​ ​uIU/ml,​ ​free​ ​thyroxine 
5.58​ ​ng/dl,​ ​total​ ​T4​ ​19.2​ ​[micro]g/dl,​ ​triiodothyronine​ ​1.7​ ​ng/ml,​ ​aspartate 
aminotransferase​ ​112​ ​U/l,​ ​alanine​ ​aminotransferase​ ​163​ ​U/l,​ ​alkaline​ ​phosphatase​ ​152 
U/l,​ ​total​ ​bilirubin​ ​0.6​ ​mg/dl,​ ​creatinine​ ​1.16​ ​mg/dl,​ ​thyroid​ ​stimulating​ ​immunoglobulin 
41%,​ ​and​ ​total​ ​ferritin​ ​717​ ​ng/mL.​ ​Chest​ ​X-ray​ ​showed​ ​the​ ​left​ ​side​ ​pleural​ ​effusion 
[Figure​ ​1].​ ​Chest​ ​computed​ ​tomography​ ​(CT)​ ​scan​ ​showed​ ​a​ ​loculated​ ​left​ ​pleural 
effusion​ ​with​ ​associated​ ​pleural​ ​thickening​ ​and​ ​adjacent​ ​atelectatic​ ​changes​ ​and​ ​no 
evidence​ ​of​ ​lymphadenopathy​ ​or​ ​parenchymal​ ​lung​ ​involvement​ ​[Figure​ ​2].​ ​In​ ​addition, 
diffuse​ ​increased​ ​hepatic​ ​attenuation,​ ​with​ ​an​ ​average​ ​of​ ​110​ ​Hounsfield​ ​units​ ​(HU) 
(normal​ ​attenuation​ ​in​ ​the​ ​liver:​ ​30–70​ ​HU),​ ​was​ ​noted​ ​on​ ​the​ ​lower​ ​chest​ ​CT​ ​scan 
images,​ ​consistent​ ​with​ ​amiodarone​ ​hepatotoxicity​ ​[Figure​ ​3].​ ​A​ ​diffusely 
heterogeneous,​ ​enlarged​ ​thyroid​ ​gland​ ​was​ ​noticed​ ​on​ ​thyroid​ ​ultrasound.​ ​Thyroid 
uptake​ ​scan​ ​showed​ ​a​ ​24​ ​h​ ​uptake​ ​of​ ​1.1%,​ ​consistent​ ​with​ ​thyroiditis.{Figure​ ​1}{Figure 
2}{Figure​ ​3} 
 
Subsequently,​ ​an​ ​ultrasound-guided​ ​diagnostic​ ​thoracentesis​ ​and​ ​a​ ​bronchoscopy​ ​with 
bronchoalveolar​ ​lavage​ ​were​ ​performed.​ ​Pleural​ ​fluid​ ​analysis​ ​showed​ ​exudative 
effusion,​ ​with​ ​WBC​ ​10,800/mm​ ​[sup]3​ ​[sup](​ ​82%​ ​polymorphs,​ ​18%​ ​lymphocytes),​ ​red 
blood​ ​cell​ ​300​ ​cells/mm​ ​[sup]3,​ ​protein​ ​2.9​ ​g/dL,​ ​glucose​ ​95​ ​mg/dL,​ ​pH​ ​-​ ​7.51,​ ​and 
lactate​ ​dehydrogenase​ ​250​ ​U/L.​ ​The​ ​pleural​ ​fluid's​ ​Gram​ ​and​ ​acid-fast​ ​stains;​ ​aerobic, 
anaerobic,​ ​fungal,​ ​and​ ​tubercular​ ​cultures;​ ​adenosine​ ​deaminase,​ ​and​ ​tumor​ ​cytology 
were​ ​negative. 
 
After​ ​excluding​ ​other​ ​causes​ ​of​ ​the​ ​loculated​ ​effusion​ ​and​ ​given​ ​the​ ​patient's 
presentation,​ ​with​ ​thyroid​ ​and​ ​hepatic​ ​toxicities​ ​secondary​ ​to​ ​long-term​ ​amiodarone​ ​use, 
the​ ​effusion​ ​was​ ​attributed​ ​to​ ​amiodarone​ ​toxicity. 
 
Given​ ​the​ ​patient's​ ​refractory​ ​arrhythmias,​ ​amiodarone​ ​was​ ​continued​ ​at​ ​a​ ​lower​ ​dose​ ​of 
200​ ​mg​ ​daily.​ ​The​ ​patient​ ​has​ ​also​ ​started​ ​on​ ​prednisone​ ​30​ ​mg​ ​daily​ ​for​ ​the 
management​ ​of​ ​both,​ ​amiodarone-induced​ ​thyrotoxicosis​ ​and​ ​lung​ ​toxicity.​ ​Three 
months​ ​after​ ​amiodarone​ ​dose​ ​reduction​ ​and​ ​prednisone​ ​tapering,​ ​the​ ​patient​ ​was 
asymptomatic​ ​and​ ​a​ ​follow-up​ ​chest​ ​CT​ ​scan​ ​showed​ ​significant​ ​improvement​ ​of​ ​the 




Amiodarone​ ​is​ ​a​ ​highly​ ​effective​ ​antiarrhythmic​ ​drug.​ ​It​ ​was​ ​initially​ ​used​ ​to​ ​treat​ ​angina 
pectoris​ ​and​ ​was​ ​later​ ​approved​ ​for​ ​the​ ​treatment​ ​of​ ​ventricular​ ​and​ ​atrial​ ​arrhythmias.​ ​It 
is​ ​currently​ ​one​ ​of​ ​the​ ​most​ ​commonly​ ​prescribed​ ​drugs​ ​in​ ​the​ ​USA,​ ​especially​ ​for​ ​the 
management​ ​of​ ​ventricular​ ​and​ ​atrial​ ​arrhythmias.​ ​Although​ ​it​ ​is​ ​considered​ ​a​ ​Class​ ​III 
antiarrhythmic​ ​drug,​ ​it​ ​also​ ​has​ ​Classes​ ​I,​ ​II,​ ​and​ ​IV​ ​actions,​ ​making​ ​it​ ​a​ ​unique​ ​and 
effective​ ​antiarrhythmic​ ​drug.​ ​Amiodarone​ ​is​ ​well-known​ ​to​ ​have​ ​many​ ​serious​ ​toxic 
adverse​ ​effects,​ ​thus​ ​limiting​ ​its​ ​long-term​ ​use.​ ​They​ ​include​ ​acute​ ​and​ ​chronic 
pulmonary​ ​toxicity,​ ​thyroid​ ​dysfunction,​ ​hepatotoxicity,​ ​dermatologic​ ​discoloration, 
corneal​ ​deposits,​ ​and​ ​peripheral​ ​neuropathy.[sup][2] 
 
Pulmonary​ ​toxicity​ ​is​ ​the​ ​most​ ​serious​ ​side​ ​effect​ ​of​ ​amiodarone.​ ​It​ ​can​ ​present​ ​as 
interstitial​ ​pneumonitis,​ ​organizing​ ​pneumonia,​ ​acute​ ​respiratory​ ​distress​ ​syndrome 
(ARDS),​ ​pulmonary​ ​nodules​ ​and​ ​masses,​ ​and​ ​very​ ​rarely​ ​pleural 
effusions.[sup][3],[4],[5]​ ​The​ ​patients​ ​usually​ ​present​ ​with​ ​cough​ ​and​ ​dyspnea​ ​and​ ​have 
infiltrates​ ​on​ ​chest​ ​X-ray​ ​or​ ​high-resolution​ ​CT.​ ​The​ ​incidence​ ​of​ ​pulmonary​ ​toxicity 
ranges​ ​from​ ​1%​ ​to​ ​10%​ ​and​ ​appears​ ​to​ ​depend​ ​on​ ​the​ ​accumulative​ ​amiodarone 
dose.[sup][1],[5]​ ​The​ ​complex​ ​mechanisms​ ​by​ ​which​ ​amiodarone​ ​causes​ ​pulmonary 
toxicity​ ​are​ ​not​ ​entirely​ ​understood.​ ​It​ ​is​ ​thought​ ​to​ ​be​ ​secondary​ ​to​ ​direct​ ​cytotoxic 
effects​ ​on​ ​type​ ​II​ ​pneumocytes​ ​and​ ​lung​ ​parenchyma​ ​or​ ​an​ ​immune-mediated 
hypersensitivity-based​ ​mechanism.[sup][6]​ ​Amiodarone​ ​pulmonary​ ​toxicity​ ​appears​ ​to 
correlate​ ​more​ ​with​ ​the​ ​total​ ​cumulative​ ​dose,​ ​rather​ ​than​ ​the​ ​daily​ ​dose​ ​or​ ​plasma 
concentration.[sup][2],[3] 
 
Pleural​ ​diseases​ ​due​ ​to​ ​amiodarone​ ​long-term​ ​therapy​ ​are​ ​rare,​ ​and​ ​they​ ​tend​ ​to 
manifest​ ​in​ ​the​ ​form​ ​of​ ​pleural​ ​thickening​ ​or​ ​effusion.[sup][7]​ ​Back​ ​in​ ​1987,​ ​Stein​ ​et​ ​al​ ​. 
were​ ​the​ ​first​ ​to​ ​report​ ​pleural​ ​effusion​ ​secondary​ ​to​ ​amiodarone​ ​treatment.[sup][8] 
Since​ ​then,​ ​nine​ ​further​ ​cases​ ​have​ ​been​ ​reported.[sup][9],[10],[11],[12],[13],[14],[15] 
Most​ ​of​ ​the​ ​patients​ ​developed​ ​pleural​ ​effusions​ ​after​ ​approximately​ ​6​ ​months​ ​of 
therapy.​ ​However,​ ​it​ ​was​ ​reported​ ​to​ ​occur​ ​as​ ​early​ ​as​ ​2.5​ ​months​ ​and​ ​as​ ​late​ ​as​ ​6 
years​ ​after​ ​amiodarone​ ​initiation.​ ​The​ ​pleural​ ​effusion​ ​can​ ​be​ ​unilateral,​ ​with​ ​a 
predilection​ ​to​ ​the​ ​right​ ​side,​ ​or​ ​bilateral.​ ​Fluid​ ​analysis​ ​usually​ ​shows​ ​a​ ​lymphocytic 
exudate,​ ​rich​ ​in​ ​proteins,​ ​and​ ​infrequent​ ​foamy​ ​macrophages.​ ​The​ ​pleural​ ​effusion​ ​is 
usually​ ​accompanied​ ​by​ ​parenchymal​ ​involvement;​ ​however,​ ​isolated​ ​pleural​ ​effusion 
has​ ​been​ ​reported.[sup][9]​ ​One​ ​case​ ​of​ ​loculated​ ​pleural​ ​effusion​ ​secondary​ ​to 
amiodarone​ ​toxicity​ ​has​ ​been​ ​reported​ ​in​ ​literature.​ ​However,​ ​the​ ​effusion​ ​was​ ​the​ ​first 
seen​ ​bilaterally​ ​and​ ​then​ ​progressed​ ​to​ ​a​ ​loculated​ ​effusion​ ​and​ ​was​ ​accompanied​ ​by 
parenchymal​ ​lung​ ​involvement.[sup][14]​ ​Our​ ​case​ ​was​ ​the​ ​first​ ​isolated​ ​loculated​ ​pleural 
effusion​ ​secondary​ ​to​ ​amiodarone​ ​toxicity​ ​without​ ​parenchymal​ ​involvement. 
 
Once​ ​the​ ​diagnosis​ ​of​ ​amiodarone​ ​pulmonary​ ​toxicity​ ​is​ ​suspected,​ ​an​ ​effort​ ​should​ ​be 
made​ ​to​ ​discontinue​ ​the​ ​drug.​ ​Worsening​ ​and​ ​progression​ ​of​ ​the​ ​disease​ ​can​ ​still​ ​be 
noted​ ​despite​ ​stopping​ ​amiodarone.​ ​This​ ​has​ ​been​ ​attributed​ ​to​ ​the​ ​long​ ​half-life​ ​of​ ​the 
drug​ ​and​ ​the​ ​tendency​ ​to​ ​concentrate​ ​in​ ​tissues​ ​such​ ​as​ ​lung.[sup][15],[16] 
Corticosteroids​ ​are​ ​the​ ​mainstay​ ​treatment​ ​of​ ​amiodarone​ ​pulmonary​ ​toxicity. 
Prednisone​ ​is​ ​usually​ ​started​ ​in​ ​doses​ ​of​ ​40–60​ ​mg​ ​daily​ ​and​ ​tapered​ ​over​ ​a​ ​4–12 
months​ ​period.​ ​Cases​ ​of​ ​relapse​ ​with​ ​early​ ​steroid​ ​withdrawal​ ​have​ ​been 
reported.[sup][17]​ ​Amiodarone-induced​ ​lung​ ​diseases​ ​usually​ ​have​ ​a​ ​good​ ​prognosis 
when​ ​diagnosed​ ​and​ ​treated​ ​early.​ ​Patients​ ​who​ ​develop​ ​ARDS​ ​or​ ​pulmonary​ ​fibrosis 
have​ ​worse​ ​prognosis.​ ​In​ ​our​ ​case,​ ​the​ ​pleural​ ​effusion​ ​improved,​ ​with​ ​oral 
corticosteroids,​ ​despite​ ​amiodarone​ ​therapy​ ​continuation​ ​as​ ​reported​ ​in​ ​previous 
cases.[sup][18]​ ​The​ ​North​ ​American​ ​Society​ ​of​ ​Pacing​ ​and​ ​Electrophysiology​ ​suggests 
yearly​ ​chest​ ​X-ray,​ ​biennial​ ​thyroid​ ​and​ ​liver​ ​function​ ​tests,​ ​and​ ​ophthalmologic 
evaluation​ ​at​ ​baseline​ ​and​ ​on​ ​any​ ​visual​ ​impairment.​ ​Pulmonary​ ​function​ ​test​ ​can​ ​be 





Our​ ​case​ ​represents​ ​a​ ​very​ ​unusual​ ​presentation​ ​of​ ​amiodarone-induced​ ​lung​ ​toxicity 
and​ ​emphasizes​ ​that​ ​amiodarone​ ​should​ ​be​ ​considered​ ​in​ ​the​ ​differential​ ​diagnosis​ ​of 
patients​ ​with​ ​exudative​ ​pleural​ ​effusions​ ​after​ ​excluding​ ​other​ ​causes.​ ​If​ ​clinically 
feasible,​ ​amiodarone​ ​should​ ​be​ ​replaced​ ​with​ ​alternative​ ​antiarrhythmic​ ​therapy​ ​when 
pulmonary​ ​toxicity​ ​is​ ​suspected,​ ​and​ ​corticosteroids​ ​therapy​ ​may​ ​be​ ​beneficial. 
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